Twist Bioscience (NASDAQ:TWST) Price Target Raised to $54.00

Twist Bioscience (NASDAQ:TWST) had its target price lifted by Robert W. Baird from $48.00 to $54.00 in a report published on Tuesday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other analysts also recently weighed in on TWST. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Scotiabank lifted their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Barclays decreased their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Wolfe Research assumed coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Finally, Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $53.80.

Twist Bioscience Trading Up 0.1 %

Shares of TWST opened at $53.70 on Tuesday. The stock has a 50-day moving average price of $48.84 and a 200-day moving average price of $46.32. The company has a market cap of $3.19 billion, a PE ratio of -14.92 and a beta of 1.87. Twist Bioscience has a 12-month low of $27.41 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. Twist Bioscience’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.75) EPS. As a group, analysts predict that Twist Bioscience will post -2.27 earnings per share for the current year.

Insider Activity

In other news, SVP Paula Green sold 860 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $45,322.00. Following the transaction, the senior vice president now directly owns 133,715 shares of the company’s stock, valued at approximately $7,046,780.50. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the sale, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. This represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 59,002 shares of company stock valued at $2,851,681. Company insiders own 3.01% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the third quarter valued at approximately $34,000. Van ECK Associates Corp boosted its position in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares in the last quarter. Signaturefd LLC boosted its position in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares in the last quarter. US Bancorp DE boosted its holdings in Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after acquiring an additional 601 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC bought a new stake in Twist Bioscience in the third quarter worth $95,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.